Results 191 to 200 of about 106,022 (294)

Perceptions of Glucagon-like Peptide 1 Receptor Agonists Among Individuals With Knee Osteoarthritis and Excess Weight: A Qualitative Study. [PDF]

ACR Open Rheumatol
Frier K, Dietl M, Aronson S, Dhani J, James K, Betensky D, Selzer F, Losina E, Katz JN, Kim JS, Weiss-Laxer NS.   +10 more
europepmc   +1 more source

Perioperative glycaemic profiles in Aboriginal and Torres Strait Islander people with diabetes mellitus

Diabetic Medicine, EarlyView.
This large multicentre retrospective cohort study in Australia revealed that despite being younger and having greater preoperative comorbidity and higher HbA1c levels, Aboriginal and Torres Strait Islander adults with diabetes mellitus demonstrate higher rates of perioperative hypoglycaemia, but otherwise comparable markers of glycaemic variability and
Katerina Flabouris, Odette R. Pearson, Kim Morey, Suzanne M. Edwards, David R. Jesudason, Chinmay S. Marathe   +5 more
wiley   +1 more source

Cardioprotective mechanisms and effects of glucagon-like peptide-1 receptor agonists in autoimmune rheumatic diseases. [PDF]

Rheumatology (Oxford)
Karacabeyli D, Lacaille D.
europepmc   +1 more source

It's a game changer in terms of diabetic management’: A qualitative study of adolescents' and parents' experiences of a 6‐month trial of continuous glucose monitoring in type 2 diabetes

Diabetic Medicine, EarlyView.
Abstract Aim To qualitatively explore adolescents with type 2 diabetes (T2D) using any treatment regimen and parents of such adolescents' experiences of a 6‐month trial of continuous glucose monitoring (CGM) and its perceived barriers and facilitators.
Maheesha Fernando, Alexia S. Peña, Ashlee King, Melissa Oxlad   +3 more
wiley   +1 more source

Efficacy and Hypoglycaemia Outcomes With Once‐Weekly IcoSema Versus Comparators in Individuals With Type 2 Diabetes by Kidney and Liver Function: A Post Hoc Analysis of the COMBINE 1–3 Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims This post hoc analysis of COMBINE 1–3 assessed efficacy and hypoglycaemia outcomes with IcoSema (once‐weekly combination therapy of basal insulin icodec and semaglutide [a glucagon‐like peptide‐1 analogue]) versus comparators in adults with type 2 diabetes (T2D) by kidney and liver function subgroups.
Linong Ji, Jonas Dahl Andersen, Malik Benamar, Paola Ponzani, A. G. Unnikrishnan, Siri Vinther, Rosangela Rea   +6 more
wiley   +1 more source

Glucagon-like peptide-1 receptor agonists and risk of depression: a systematic review and meta-analysis. [PDF]

BMC Psychiatry
Bi Z, Jiao Z, Li J, Fang Z.
europepmc   +1 more source

GLP‐1‐Based Therapies in Type 1 Diabetes: Emerging Evidence on Cardiovascular, Renal, and Safety Outcomes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Individuals living with type 1 diabetes (T1D) are at increased risk for cardiovascular (CV) and renal complications, yet therapeutic strategies specifically targeting cardiorenal risk reduction in this population remain limited. The role of glucagon‐like peptide‐1 (GLP‐1)‐based therapies in T1D remains unclear.
Anastasios Tentolouris, Djordje S. Popovic, Alexandros L. Liarakos, Alexandros Briasoulis, Nikolaos Papanas, Theocharis Koufakis   +5 more
wiley   +1 more source

Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists in Parkinson Disease: A Systematic Review and Meta-Analysis. [PDF]

Brain Behav
Raza H, Nizam B, Padaniya A, Farid MA, Nabi A, Hasan MQ, Salih M, Patel AH, Inam N, Rehman MEU, Khan U, Alsubari AMA.   +11 more
europepmc   +1 more source

State‐Level Variation in Glucagon‐Like Peptide‐1 Receptor Agonists Fills and Spending by Obesity Prevalence, 2023

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Tamkeen Khan, Stavros Tsipas, Fleetwood Loustalot, Lindsay Zasadzinski, Klodiana Myftari, Alyson B. Goodman, Gregory D. Wozniak   +6 more
doaj   +1 more source